Novo Nordisk's semaglutide helps a significant proportion of children aged 6-11 achieve a healthier weight in breakthrough trial

Novo Nordisk reports promising results from a late-stage trial showing that its obesity drug semaglutide enables nearly 40% of children aged six to under 12 to reduce their BMIs below the obesity threshold, signalling a potential shift in paediatric obesity…













